INFI - Infinity Pharmaceuticals to Present at Upcoming BIO CEO & Investor Conference
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that management will be presenting at the BIO CEO & Investor Conference taking place February 16-18. Presentations details are below:
BIO CEO & Investor Conference Presentation Details: |
Date: |
February 16 – 18 |
Presentation: |
Available on demand starting February 16 th at 10am EST |
The link for the presentation will be available at www.infi.com . |
About Infinity and Eganelisib
Infinity is an innovative biopharmaceutical company dedicated to developing novel medicines for people with cancer. Infinity is advancing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, in multiple clinical studies. MARIO-275 is a Phase 2, randomized, placebo-controlled study of eganelisib combined with Opdivo in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq ® and Abraxane ® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil ® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line and second line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com .
Opdivo ® is a registered trademark of Bristol Myers Squibb.
Tecentriq ® is a registered trademark of Genentech, Inc.
Abraxane ® is a registered trademark of Abraxis BioScience, LLC.
Avastin ® is a registered trademark of Genentech, Inc.
Doxil ® is a registered trademark of Baxter Healthcare Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005569/en/
Investor Relations Contact:
Ashley Robinson
LifeSci Advisors, LLC
617-775-5956